GLOBAL HEALTH ECONOMICS AND OUTCOMES RESEARCH AMGEN (AMGN)
Biotechnology association Amgen Inc. (AMGN) saw a cost of a shares tumble from a tall of $77 to around $55 as of Oct 2, 2007. The decrease in Amgen batch followed headlines of marked down sales forecasts for a best-selling drug, Aranesp. With disappearing revenues from drug sales, Amgen is being forced to trim expenditures. The association voiced it was laying off in in in between twelve – 14% of a workforce as well as programmed to cut collateral expenditures by $1.9 billion. See a compared headlines story is a resources box.
Surprisingly, Amgen skeleton no rebate in staff in a Global Health Economics as well as Outcomes Research (HEOR) unit. This section comprises a mixture of professionals with Ph.D.s in economics, pharmacists, healing doctors, as well as assorted analysts with interpretation strategy backgrounds. Their idea is to investigate pre-clinical hearing pattern as well as post-clinical hearing interpretation to remove a small causal attribute in in in between an Amgen drug as well as a sure great to clinical hearing patients. Normally, a efficient healing doctors supervising a clinical hearing during margin locations can comply possibly a drug is carrying any sure great for patients. These doctors have been ideally able of assessing a efficiency of a drug being evaluated in a clinical trial.
The HEOR section is called to movement to determine statistically what a doctors explain they comply in a margin as well as to try to find additional, unintended benefits from a drug so which Amgen can request for a obvious upon a unintended consequence. Due to a vast series of clinical trials which do not exhibit efficiency of due drugs, a initial work of Amgen’s HEOR section seems to be salvaging any probable worth or have make have make use of of of of for an Amgen drug deserted by a healing community.
There is a excellent line in in in between utilizing interpretation to spell out a deeply dark great for patients contra perplexing to find a great where nothing exists. Relying upon assorted statistical methods, Amgen’s HEOR staff proposes causal relations as well as desperately seeks interpretation to endorse them. Only people with a sure genius can be wild by a every day awaiting of sifting by rubbish in hopes of anticipating a diamond.
From what a HEOR staff told me, upon as well as upon a interpretation strategy goes perplexing to infer a drug deserted by a healing professionals in clinical trials do in actuality uncover a small obscure, mostly trivial, great to patients. The Health Economics as well as Outcomes Research staff would similar to to hold it is smarter than a doctors in a field, since a HEOR staff explain they can find healing benefits which doctors treating patients unsuccessful to observe. In my opinion, a Amgen HEOR staff investigate models as well as their statistical formula have been mostly tenuous, during best, as well as ludicrous, during worst. we learn Health Care Economics during both a undergraduate as well as connoisseur level. Having seen how my undergraduate students critique illness caring process initiatives as well as a curative industry, we have no disbelief they would simply rip detached a assumptions, analyses, as well as conclusions of a Amgen HEOR studies as well as reports. Investors have to consternation because Amgen spends an estimated $25 million in salaries for a HEOR professionals if their outlay is receptive to reprove by undergraduate students with no curative training.
Another pointer of a bad peculiarity of Amgen’s Health Economics section is a miss of publications. Amgen positively takes honour when a staff can get investigate formula published in peer-reviewed journals. Professional biography publications by Amgen staff assist a company’s selling campaigns, supplement to a status of a company, as well as assistance capacitate them to partisan heading scientists. On Oct 2, 2007, we searched a Nexis “All Full-Text Medical Journals” database regulating a keyword “AMGEN” in a same judgment as “Health Economics” or “Outcomes Research.” A sum of 0 articles were found. we afterwards steady this same poke regulating a “All Medline Review Article References,” which contains biography publications pre-1975 to a present. A grand sum of a single essay appeared entitled “Psychological outcomes compared with anemia-related tired in cancer patients,” which relates to Amgen’s right divided disappearing sales drug Aranesp. Desperate to find a small justification of discernible published investigate by Amgen’s HEOR unit, we afterwards searched a database called “Healthcare Archive News,” which contains broadside announcements as well as press releases about even teenager systematic as well as healing investigate findings. The database contained 0 articles about any Amgen HEOR healing commentary though did list a couple of press releases connected with a appointments of David Beier as well as Joshua Ofman to lead Amgen’s HEOR group.
In a tumble of 2005, we was invited to revisit Amgen’s domicile in Thousand Oaks, California, as well as delivered a speak upon a ultimate treatments for osteoporosis. The upshot of my speak was which Novartis’s bisphosphonate drug, Zometa (known generically as Zoledronic Acid) represented a many suitable as well as strongest probable diagnosis to forestall bone fractures in post-menopausal women pang from osteoporosis. Zometa is a drug used by oncologists to have organisation a bone have up caused by calcium leaching from patients subjected to sure forms of chemotherapy. In my speak to review a efficiency of Zometa to alternative bisphosphonates, we indicated which a verbal bisphosphonates (pills), such as Fosamax as well as Actonel, were similar to palm guns, whilst Zometa (given intravenously) was similar to a howitzer. we remarkable which in Nov 2005, a FDA usually authorized Zometa as a diagnosis for a consequences of chemotherapy; however, my contacts inside of Novartis referred to me a association would shortly launch a clinical hearing to enhance a have make have make use of of of of of this drug for diagnosis of osteoporosis as well as low bone vegetable density.
I privately celebrated an aged studious in her 80s outing as well as as well as means a dire tumble face down upon a petrify driveway, nonetheless she postulated no detonate anywhere upon her physique interjection to prior to treatments with Zometa. The studious struck a petrify with such force which her eyeglasses were knocked off her conduct as well as landed 6 feet divided during a bottom of a small bushes. This same studious had postulated a devalue hip detonate a couple of years progressing whilst receiving weekly Fosamax pills. In an a single more episode, an octogenarian thin studious fell retrograde as well as struck her conduct so tough as to means her to be dazed, nonetheless she suffered no detonate of her fundamental have up anywhere — all interjection to a efficiency of Zometa to have organisation a frail skeleton of osteoporotic patients.
Before we could even finish my talk, a illuminaries from Amgen’s Outcomes Research section began caviling during my conclusions. First, a 50-year aged Senior Analyst, with gray, curly, shoulder-length hair, who ready to go for work any day in blue jeans as a insurgent opposite a suit-and-tie culture, conspicuous nothing of my conclusions were upheld by clinical trials. we responded which diagnosis of osteoporosis with Zometa was afterwards state-of-the-art disinfectant still years forward of clinical trials, as well as which anecdotal box studies such as this were mostly a source of ideas to be tested with clinical trials.
The Amgen Senior Analyst conspicuous he would not accept any of my conclusions, nor allegedly would any efficient professional, though a double-blind remedy clinical trial. This same researcher told me after my speak which he had been invited to conduct a Health Economics as well as Outcomes Research units during dual alternative curative companies, nonetheless formed upon his astigmatic comments, we severely doubted it. Again, we responded to a Senior Analyst by asking if his own aged mom or aunt or uncle had formerly suffered a bone detonate as well as was in risk of carrying a significantly marked down peculiarity of hold up with any serve fracture, would he rest upon a diseased FDA-approved verbal bisphosphonates or try to get Zometa caring for his own relatives? He answered he would hang with a FDA-approved drugs, even if it meant his aged primogenitor would be feeble with an a single more hip detonate from which he or she competence not redeem as well as would fast mellow in bed as well as die.
Next, a 6’3″ house authorized radiologist, who for a small unexplained reason gave up an annual income of $350,000+ as a radiologist in in isolation have make use of of to turn an attention penetrate operative for Amgen, carped which bisphosphonates, such as Zometa, do not essentially stop a leaching of calcium from skeleton though instead have organisation a hideaway have up of a bone. Furthermore, my speak enclosed no head-to-head comparisons of Zometa with Fosamax or Actonel or any alternative verbal bisphosphonate, so he would not accept a conclusion. we responded by asking a radiologist how many patients he had treated with colour for osteoporosis whilst in in isolation practice. He responded “none.”
I asked a radiologist if he knew a state-of-the-art treatments for osteoporosis as of 2005, as well as he responded which a verbal bisphosphonates were a state-of-the-art. we afterwards forked out which no house authorized oncologist would cruise a verbal bisphonates for treating cancer victims with enervated bone structures from chemotherapy. Oncologists need a healing homogeneous of a “howitzer” not a cocktail gun to have organisation their cancer patients’ bones, as well as oncologists’ elite drug for this diagnosis was Zometa. Osteoporosis has many of a same characteristics of enervated bone have up as well as low bone vegetable firmness as occurs with cancer patients who have undergone sure sorts of chemotherapy. Despite his objections, we stood by my conclusions which Zometa was a many suitable accessible diagnosis for osteoporosis, as well as we would suggest it as a life-saving diagnosis for aged patients (male or female) receptive to immobilizing fractures.
I approaching Amgen’s Health Economics staff to be discreet in describing non-FDA authorized have make have make use of of of of of drugs, though we did not expect anticipating an complete dialect filled with narrow-minded, rigid, demagogues unqualified of meditative outward a box. To them, it was possibly a Amgen approach (methodology) or no approach during all. The Amgen HEOR youth analysts had antacid expressions upon their faces during my talk, as well as when we asked them if they would let their own relatives or grandparents die from a debilitating consequences of a hip detonate or get them Zometa caring if needed, they took their justification from a 6’3″ oncologist as well as conspicuous regularly they would “let grandma die.” Do we unequivocally wish inhuman people similar to this concerned in contrast a nation’s drug pipeline?
After my talk, we met a single more staff in a Amgen HEOR unit, as well as any a single incited out to be rebate considerable than a final one. One of a final people we met was a pharmacist with illness economics shortcoming for cardiology drug being grown by Amgen. He told me he had small credentials in economics as well as hence could not write any articles befitting for announcement in economics journals. Yet, he claimed he knew how to rise a initial cost which any curative organisation should assign for any code brand new drug being brought to a market. In economics, a cost for a normal great is dynamic as an balance indicate by a intersection of direct as well as supply. But this pharmacist had no have make have make use of of of of for direct as well as supply concepts as well as seemed to erect prices for drug with his own ad hoc methods.
Amgen’s HEOR section is filled with people who have been out of hold with a illness caring complement in America. The gray, shoulder-length haired Senior Analyst during Amgen, for example, referred to a initial reason people select to go though illness word is which they hold they have been godlike as well as have been peaceful to play upon their health. Given a strenuous justification upon miss of affordable illness word for a operative poor, if a tyro in possibly my undergraduate or connoisseur Health Care Economics incited in an choice with an inane criticism similar to that, we would have a tyro repeat which assignment.
Approximately dual years after my speak during Amgen, a Associated Press circulated a national story upon Sept. 18, 2007, with a lead paragraph, “For a initial time, an osteoporosis drug has marked down deaths as well as prevented code brand new fractures in aged patients with damaged hips . . . .No alternative osteoporosis drug investigate published in a final fifteen years has shown such a conspicuous rebate in deaths.” What is a drug referred to in this study? ZOMETA (marketed by Novartis for osteoporosis patients underneath a code name Reclast). Two years prior to a Associated Press article, we likely this drug would turn a many manly diagnosis for osteoporotic patients in risk of hip as well as alternative bone fractures. Amgen’s shining HEOR staff deserted which forecast.
In my opinion, a Amgen HEOR staff needs to be consummated or reassigned to alternative areas where it can minister to a company’s bottom line. Its curative economics displaying as well as interpretation manipulations appear dubious, as well as it appears ethically controversial to investigate interpretation with a dictated idea of proof an Amgen drug deserted in clinical trials has a small healing great which doctors in a margin overlooked. If Amgen’s CEO as well as tip government have been critical about slicing costs as well as expelling nonessential expenses, afterwards they need to begin by expelling a Global Health Economics as well as Outcomes Research unit. Until a HEOR section is eliminated, we will go on to perspective Amgen as a feeble managed association with a bloated, sterile staff.
QUESTIONS FOR MANAGERIAL ECONOMICS STUDENTS
1. Describe a magnitude of pursuit pattern in formulating a positions inside of Amgen’s HEOR unit.
2. Do we hold a pursuit pattern is suitable for this firm? How would we magnitude a prolific outlay of staff in Amgen’s HEOR unit?
3. What suggestions do we have for mending a pursuit pattern of Amgen’s HEOR staff? Should curative companies occupy staff in this area?
4. Assume we have been a physical education instructor of Amgen tasked with expelling a HEOR unit. What is a many suitable approach to exercise your task?